<DOC>
	<DOCNO>NCT00655252</DOCNO>
	<brief_summary>This expand access study design provide RAD001 patient MRCC without satisfactory treatment alternative , RAD001 become commercially available .</brief_summary>
	<brief_title>Expanded Access Study RAD001 Metastatic Renal Cell Cancer Patients Who Are Intolerant Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Inclusion criterion : ≥ 18 year old ; metastatic renal cancer , intolerant fail sunitinib and/or sorafenib Adequate bone marrow function , liver function , renal function Adequate birth control Exclusion criterion : Previously receive RAD001 mTOR inhibitor , know hypersensitivity rapamycin , chronic systemic treatment corticosteroid immunosuppressive agent ( prednisone ≤ 20 mg/day adrenal insufficiency OK Topical inhale steroid OK ) Active bleeding Uncontrolled angina , CHF , heart attack ≤ 6 month , uncontrolled diabetes Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Expanded access</keyword>
	<keyword>metastatic renal cell cancer</keyword>
	<keyword>progression despite VEGF receptor</keyword>
</DOC>